<div id="readability-page-1">SSY Group ( (HK:2005) ) just unveiled an update.SSY Group has secured approval from China’s National Medical Products Administration for the production and registration of Safinamide Mesylate Tablets in 50mg and 100mg strengths, classified as a type 4 chemical drug and deemed to have passed consistency evaluation. The drug, used as combination therapy for adult patients with primary Parkinson’s disease experiencing symptom fluctuations, builds on prior approval of the Group’s Safinamide bulk drug and reinforces its position in the neurological treatment segment.The company has also obtained NMPA approval for Procaterol Hydrochloride Inhalation Solution, a type 3 chemical drug indicated for relieving airflow limitation symptoms in bronchial asthma, chronic bronchitis and emphysema. These dual approvals broaden SSY Group’s portfolio in both central nervous system and respiratory therapies, potentially strengthening its competitive stance in China’s generic and specialty drug markets and signaling ongoing progress in its product development pipeline. The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page. <div> More about SSY Group SSY Group Limited is a pharmaceutical company based in Hong Kong, operating through subsidiaries in China. The Group focuses on developing, manufacturing and registering chemical drugs for the Chinese market, targeting therapeutic areas such as neurological disorders and respiratory diseases. YTD Price Performance: -23.74% Average Trading Volume: 6,323,423 Technical Sentiment Signal: Sell Current Market Cap: HK$6.29B </div><div> For an in-depth examination of 2005 stock, go to TipRanks’ Overview page. </div></div>

02005

SSY Group (HK:2005) received NMPA approvals for Safinamide Mesylate Tablets for Parkinson's disease and Procaterol Hydrochloride Inhalation Solution for respiratory conditions. These approvals expand the company's portfolio in neurological and therapeutic segments, reinforcing its competitive position in China's generic drug market.

SSY Group Wins NMPA Approvals for Parkinson’s and Respiratory Drugs